



Hi-Affi™ Recombinant Human Anti-VEGFA

Monoclonal antibody, clone G6 (DMAB-CS25220)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

| | |
|---------------------------|--|
| Product Overview | G6 is a synthetic antibody derived from phage display libraries that has the ability to bind and neutralize both human and murine vascular endothelial growth factor (VEGF). |
| Specificity | G6 recognises a VEGF epitope which is conserved between human and mouse VEGF and overlaps with the receptor binding surface. |
| Target | Human/Mouse VEGFA |
| Immunogen | The anti-mVEGF Fab G6 underwent light chain randomisation by placing stop codons in positions 91-96 in CDR-L3 and an equimolar mix of oligonucleotides designed for mutagenesis was annealed to the mV401 stop template phagemid, followed by mutagenesis and E. coli electroporation. Binding selection was performed with mVEGF immobilised on immunoplates followed by solution-phase sorting with increasing stringency and single-point competitive ELISA to screen for high-affinity clones. |
| Isotype | IgG |
| Source/Host | Human |
| Species Reactivity | Human, Mouse |
| Clone | G6 |
| Purification | >90% determined by SDS-PAGE |
| Conjugate | Unconjugated |
| Applications | Crystallography, SPR, BL, ELISA, IF |

Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.

| | |
|----------------------|--|
| Format | Liquid |
| Concentration | lot specific |
| Size | 200 µg, 1 mg |
| Buffer | PBS (endotoxin < 1EU/mg, lower endotoxin levels may also be offered upon request) |
| Preservative | None |
| Storage | Short term at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles. |
| Ship | Dry ice |

BACKGROUND

Introduction Vascular endothelial growth factor (VEGF) is a highly specific angiogenic growth factor; anti-angiogenic treatment through inhibition of receptor activation by VEGF might have important therapeutic applications in diseases such as diabetic retinopathy and cancer.

Keywords Vascular endothelial growth factor; VEGF; VEGFA; VPF